Ibandronate provides efficacy and safety in the treatment of metastatic bone disease

European Journal of Cancer, Supplement

Volumn 4, Issue 8, 2006, Pages 13-18

  von Moos, Roger ^a  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Acute phase reaction; Bisphosphonates; Ibandronate; Osteonecrosis of the jaw; Renal safety; Skeletal related events

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; MARKER; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACUTE PHASE RESPONSE; ADVANCED CANCER; ANALGESIA; ARTICLE; BLOOD LEVEL; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGITIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; JAW; KIDNEY FAILURE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RISK REDUCTION; URINE LEVEL; VERTEBRA FRACTURE;

EID: 33747345080     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2006.07.004     Document Type: Article

References (53)

1. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 16 (2004) 1655-1664
2. McCormack P.L., and Plosker G.L. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs 66 5 (2006) 711-728
3. Heidenreich A., Ohlmann C., and Body J.J. Ibandronate in metastatic bone pain. Semin Oncol 31 5 Suppl. 10 (2004) 67-72
4. Mancini I., Dumon J.C., and Body J.J. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22 17 (2004) 3587-3592
5. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 9 Suppl. 4 (2004) 14-27
6. Body J.J., Diel I.J., Lichinitzer M., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 90 6 (2004) 1133-1137
7. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 14 9 (2003) 1399-1405
8. Scott M., Möcks J., and Givens S. Morbidity measures in the presence of recurrent composite endpoints. Pharm Stat 2 1 (2003) 39-49
9. Body J.J., Kanis J., and Diel I.J. Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate. J Clin Oncol 22 Suppl. (2003) 46 Abstract 184
10. Tripathy D. Oral daily ibandronate: an effective and convenient therapy for skeletal complications in metastatic breast cancer. Eur J Cancer Suppl 2 5 (2004) 17-20
11. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 1 (2005) 59-69
12. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 22 (2005) 4925-4935
13. Lipton A., Hei Y., Coleman R., Major P., and Cook R. Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome. J Clin Oncol 23 Suppl. 16s (2005) 11s Abstract 532
14. Smith M.R. Markers of bone metabolism in prostate cancer. Cancer Treat Rev 32 Suppl. 1 (2006) 23-36
15. Body J.J., Lichinitser M.R., Tjulandin S., Budde M., and Bergström B. Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial. J Clin Oncol 23 Suppl. 16s (2005) 12s Abstract 534
16. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23 15 (2005) 3314-3321
17. Tripathy D., and Budde M. Assessing the efficacy of ibandronate for the prevention of skeletal-related events (SREs) in metastatic bone disease: a methodological comparison. Bone 34 Suppl. 1 (2004) S91-S92
18. Bergström B., Lichinitser M.R., and Body J.J. Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative phase III trials. Bone 38 Suppl. 1 (2006) S68-S69
19. Tanvetyanon T., and Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17 6 (2006) 897-907
20. Paterson A.H., Powles T.J., Kanis J.A., McCloskey E., Hanson J., and Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11 1 (1993) 59-65
21. Robertson A.G., Reed N.S., and Ralston S.H. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13 9 (1995) 2427-2430
22. ® treatment of metastatic bone disease in breast cancer. Bone 38 Suppl. 1 (2006) S83 Abstract 104
23. Body J.J., Diel I.J., Tripathy D., and Bergström B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care 15 3 (2006) 299-302
24. McLachlan S.A., Cameron D., Murray R., Tripathy D., and Bergström B. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Invest 26 1 (2006) 43-48
25. Henrich D., Bergner R., Hoffmann M., Honecker A., Nagel D., and Uppenkamp M. Open-label study of ibandronate in elderly myeloma patients with pre-existing renal deterioration. Blood 106 11 (2005) Abstract 3459
26. Munier A., Gras V., Andrejak M., et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 39 7-8 (2005) 1194-1197
27. Chang J.T., Green L., and Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 349 17 (2003) 1676-1679
28. Mazj S., and Lichtman S.M. Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics. J Clin Oncol 22 Suppl. (2004) 8039
29. Stein S.H., Davidson E., Tweed A., et al. Renal dysfunction with IV bisphosphonates in patients with metastatic breast cancer. J Clin Oncol 22 Suppl. (2003) 745 Abstract 2997
30. Jones S.G., Dolan G., Lengyel K., and Myers B. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol 119 2 (2002) 576-577
31. Markowitz G.S., Fine P.L., Stack J.I., et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64 1 (2003) 281-289
32. Markowitz G.S., Fine P.L., and D'Agati V D. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 39 5 (2002) 1118-1122
33. Janssen van Doorn K., Neyns B., Van der Niepen P., and Verbeelen D. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron 89 4 (2001) 467-468
34. Lockridge L., Papac R.J., and Perazella M.A. Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis. Am J Kidney Dis 40 1 (2002) E2
35. Buysschaert M., Cosyns J.P., Barreto L., and Jadoul M. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 18 4 (2003) 826-829
36. Barri Y.M., Munshi N.C., Sukumalchantra S., et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65 2 (2004) 634-641
37. Smetana S., Michlin A., Rosenman E., Biro A., Boaz M., and Katzir Z. Pamidronate-induced nephrotoxic tubular necrosis - a case report. Clin Nephrol 61 1 (2004) 63-67
38. Kunin M., Kopolovic J., Avigdor A., and Holtzman E.J. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant 19 3 (2004) 723-726
39. ® (zoledronic acid) US Product Information. December 2005.
40. ® (zoledronic acid) European Product Information. January 2006.
41. ® (ibandronate) European Product Information. August 2005.
42. Pfister T., Atzpodien E., and Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191 2-3 (2003) 159-167
43. Pfister T., Atzpodien E., Bohrmann B., and Bauss F. Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 97 6 (2005) 374-381
44. Heidenreich A., Elert A., and Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5 3 (2002) 231-235
45. Heidenreich A., Ohlmann C., Olbert P., and Hegele A. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer. Eur J Cancer 1 Suppl. 5 (2003) S270 Abstract 897
46. Ohlmann C., and Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer 11 (2003) 396 Abstract A-38
47. von Moos R., Cathomas R., Egli F., and Inauen R. Experience with loading-dose ibandronate. Bone 38 Suppl. 1 (2006) S86 Abstract 111
48. Heidenreich A., Ohlmann C., and Bergner R. Renal safety of loading-dose ibandronate in urologic patients with compensated renal insufficiency. Cancer Treat Rev 31 Suppl. 1 (2005) S50-S51 Abstract 95
49. Body J.J., Lichinitser M.R., Andreeva N., Budde M., and Bergstrom B. Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease: results of an open-label study. J Clin Oncol 22 Suppl. 14S (2004) 60 Abstract 735
50. Migliorati C.A., Casiglia J., Epstein J., Jacobsen P.L., Siegel M.A., and Woo S.B. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136 12 (2005) 1658-1668
51. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 1 (2005) 99-102
52. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 5 (2004) 527-534
53. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 11 (2005) 1567-1575